Valink Therapeutics
Discovering bispecific antibody drug-conjugates (BsADC) against cancer
Biotech
Therapeutics
Drug discovery
About
Valink Therapeutics develops next generation antibody-based therapeutics. We identify novel mechanism of action from known targets by incorporating multiple antibody modifications at once, rapidly and scalable generating complex drug candidates (bi-/multispecificity, multivalency and drug-conjugation in a single discovery process). Our research focus is on solid tumours poorly addressed by immunotherapy.
Build your own investing agent
GPAgent keeps YC listings public and neutral. Fund-specific scoring, notes, and workflow state live in each customer workspace.
Join the GPAgent waitlistDetails
Status
Active
Stage
Early
Team Size
15
Regions
United States of America, America / Canada, Remote, Partly Remote